ongoing

In patients receiving a factor Xa inhibitor who are experiencing an acute major bleed, the objectives of the ANNEXa-4 study are to:

  • Demonstrate the decrease in anti-fXa activity and;
  • Evaluate hemostatic efficacy following andexanet treatment.
Study Type

Interventional - Drug

Study Design

Prospective open-label

NO. of Countries

9

NO. of Sites

81

NO. of Participants

466

Study Period

2015 - 2020

Sponsor

Portola Pharmaceuticals

Back To Top